| Psoriatic arthritis | Univariate | Final model | ||
| HR | p | HR | p | |
| Gender, women versus men | 2.46 (0.86 to 7.08) | 0.1 | 2.48 (0.86 to 7.17) | 0.09 |
| Age, years | 1.00 (0.96 to 1.04) | 1.0 | 1.00 (0.96 to 1.04) | 0.9 |
| Methotrexate use, no versus yes | 0.68 (0.22 to 2.12) | 0.5 | – | – |
| Patient’s global score, mm | 1.01 (1.00 to 1.03) | 0.2 | – | – |
| DAS28 | 1.21 (0.79 to 1.85) | 0.4 | – | – |
| CRP, mg/L | 0.99 (0.92 to 1.07) | 0.9 | – | – |
| Longer CT-P13 interval, weeks | 0.84 (0.60 to 1.19) | 0.3 | – | – |
| Higher CT-P13 dose, mg/kg | 1.11 (0.74 to 1.67) | 0.6 | – | – |
| INX start year, 2000–2007 versus 2008–2015 | 1.11 (0.42 to 2.98) | 0.8 | – | – |
| Number of comorbidities | 0.93 (0.45 to 1.93) | 0.8 | – | – |